Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Forecasted Market Size of the Pleural Diseases Market by 2029?
The pleural diseases market size has grown strongly in recent years. It will grow from $4.86 billion in 2024 to $5.21 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rising incidence of pleural effusion, growing awareness about pleural diseases, increasing focus on early diagnosis, growing number of healthcare facilities, and rising number of pleural disease clinical trials.
The pleural diseases market size is expected to see strong growth in the next few years. It will grow to " $6.88 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to rise in the prevalence of pleural diseases, rise in the aging population, increasing number of occupational hazards, rise in the number of clinical trials, and growing number of diagnostic centers. Major trends in the forecast period include advancements in diagnostics, advancements in diagnostic tools, adoption of minimally invasive procedures, improved drug development, and telemedicine adoption.
Get your free report sample today:
What Are the Significant Market Forces Driving the Pleural Diseases Market Performance?
The increasing prevalence of infectious diseases are expected to drive the growth of the pleural diseases market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. Environmental changes to human behavior and advancements in global travel influence the increasing prevalence of infectious diseases. Infectious diseases such as bacterial pneumonia, tuberculosis, or viral infections can cause pleural disease by triggering inflammation, infection, or fluid accumulation in the pleural cavity. For instance, in January 2023, according to the National Library of Medicine, a US-based medical library for research and information, infectious diseases account for over 52 million deaths annually, placing half of the global population at risk. Further, each year, approximately 14 million children under the age of five die, with 70% of these deaths attributed to diseases that could be prevented through vaccination. Therefore, the increasing prevalence of infectious diseases drives the growth of the pleural diseases market.
What Are the Primary Market Segments in the Pleural Diseases Market?
The pleural diseasesmarket covered in this report is segmented –
1) By Disease Type: Pleurisy; Pleural Effusion; Pneumothelioma; Mesothelioma; Other Disease Types
2) By Treatment Modalities: Medications; Thoracentesis And Pleurodesis; Minimally Invasive Interventions; Surgical Interventions
3) By Diagnostic Tools: Imaging Techniques; Molecular Diagnostics; Thoracoscopy; Pleuroscopy
4) By End User: Hospitals And Clinics; Diagnostic Centers; Research And Academic Institutions
Subsegments:
1) By Pleurisy: Acute Pleurisy; Chronic Pleurisy; Infectious Pleurisy; Non-infectious Pleurisy
2) By Pleural Effusion: Transudative Pleural Effusion; Exudative Pleural Effusion; Malignant Pleural Effusion; Parapneumonic Pleural Effusion; Hemothorax; Chylothorax
3) By Pneumothelioma: Primary Pneumothelioma; Secondary Pneumothelioma (Metastatic); Localized Pneumothelioma; Diffuse Pneumothelioma
4) By Mesothelioma: Pleural Mesothelioma; Peritoneal Mesothelioma; Pericardial Mesothelioma; Testicular Mesothelioma
5) Other Disease Types: Pulmonary Embolism; Fibrothorax; Pneumothorax; Lung Cancer; Tuberculosis-Related Pleural Disease; Sarcoidosis
What Are the Current Trends Influencing the Pleural Diseases Market?
Major companies operating in the pleural diseases market are focusing on developing innovative treatment options, such as developing ready-to-use injectable treatments, to improve convenience, reduce preparation time, and minimize dosing errors. Ready-to-use injectable treatments are pre-formulated, pre-diluted medications that require no reconstitution or mixing before administration, ensuring accuracy, convenience, and reduced preparation time. For instance, in April 2024, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched PEMRYDI RTU, the first ready-to-use version of pemetrexed for injection. This helps people with pleural diseases by providing a convenient, ready-to-use treatment that eliminates the need for reconstitution or dilution, reduces preparation time, minimizes the risk of dosing errors, and improves access to effective therapy for conditions like malignant pleural mesothelioma.
Who Are the Established and Emerging Companies Competing in the Pleural Diseases Market?
Major companies operating in the pleural diseases market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, GSK plc, Astrazeneca plc, Koninklijke Philips N.V., Becton Dickinson and Company, Boehringer Ingelheim International GmbH, Sanofi SA, Penn Medicine, Henry Ford Health, Dragerwerk AG, Emory Healthcare, Boston Medical Center, Cook Medical, WakeMed, Weill Cornell Medicine, Fox Chase Cancer Center, B. Braun SE, Bicakcilar, Redax S.p.a, Rocket Medical
Get the detailed pleural diseases market report today
Which Region Is Expected to Dominate the Pleural Diseases Market During the Forecast Period?
North America was the largest region in the pleural diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pleural diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment